A New Approach to Pulmonary Fibrosis Research: Introducing SMC Laboratories’ IPF Model
SMC Laboratories, Inc. (Tokyo, Japan) is a preclinical CRO specializing in pharmacological evaluations using disease animal models. We are pleased to highlight our enhanced service offering for drug development in pulmonary fibrosis: the Idiopathic Pulmonary Fibrosis (IPF) model.
■ Low-Stress Monitoring with SpO₂ Measurement
We have recently introduced SpO₂ (oxygen saturation) monitoring using a pulse oximeter in mice. This technique imposes minimal stress on the animals and is well-suited for repeated, in-life monitoring of disease progression and therapeutic efficacy over time.
■ Enhanced Structural Assessment via Micro-CT
To complement functional evaluations, SMC also offers analysis using micro-CT for small animals. This enables non-invasive, structural visualization of lung fibrosis, providing critical insights into fibrotic progression that cannot be assessed through SpO₂ alone. The combination of SpO₂ and CT imaging offers a more comprehensive evaluation of lung function and pathology.
We welcome inquiries about our IPF model and other disease models. Our scientific team is available for online meetings to introduce our capabilities and discuss how our platform can support your research.